Business
Xenon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Last patient enrolled in XEN1101 Phase 2 X-NOVA clinical trial in major depressive disorder with topline data expected in late November to mid-December
About this update from Xenon Pharmaceuticals Inc.
[{"type":"text","content":"Last patient enrolled in XEN1101 Phase 2 X-NOVA clinical trial in major depressive disorder with topline data expected in late November to mid-December Continued progress across all XEN1101 Phase 3 epilepsy programs including in X-TOLE2 and X-TOLE3 clinical trials in focal onset seizures and X-ACKT in primary generalized tonic-clonic seizures Xenon to host XEN1101 MDD Webinar in mid-September to discuss Kv modulation in MDD, the X-NOVA clinical trial and the broader MDD landscape Conference call at 4:30 pm ET today VANCOUVER, British Columbia, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update. Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer, stated, “We are pleased to announce that patient enrollment is complete in our XEN1101 Phase 2 “X-NOVA\" study in major depressive disorder, or MDD. We expect the last patient to be randomized in the near term and anticipate more than 160 total patients will be randomized, which exceeds our planned target of 150 patients. We look forward to X-NOVA topline data in late November to mid-December. In advance of these results, we will be hosting a webinar in mid-September to review the MDD landscape and the potential of the Kv mechanism to treat MDD as well as details on our X-NOVA clinical trial.” Mr. Mortimer continued, “We are also excited about the advancements across our broad XEN1101 Phase 3 epilepsy program, including continued progress in our X-TOLE2 and X-TOLE3 clinical trials in patients with focal onset seizures and in our X-ACKT clinical trial in patients with primary generalized tonic-clonic seizures. Lastly, we are looking forward to a read-out from our Phase 2 partnered program with Neurocrine in the fourth quarter of this year.” Highlights and Anticipated Milestones XEN1101 XEN1101 is a differentiated Kv7 potassium channel opener being developed for the treatment of epilepsy and other neurological disorders, including major depressive disorder, or MDD. XEN1101 for Epilepsy (Focal Onset Seizures) Xenon’s XEN1101 Phase 3 epilepsy program includes two identical Phase 3 clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase 2b X-TOLE clinical trial. These mult...